Freespira has been proven to deliver clinical results as well as financial savings

Clinical Results

83%

Protocol adherence

85%

Panic free immediately post-treatment (tx)

81%

Panic free 12 months post-tx

Reduction in panic symptoms 12 months post-tx


Learn more about clinical studies that prove
the safety and efficacy of Freespira

Stanford Trial Overview Multi-Center Trial Overview Highmark Health Program
Stanford Trial Overview Overview In 2008, a randomized-controlled clinical trial treating panic disorder was published. At one year following the four-week treatment period, 68% of subjects were panic-free and 93% had significant reductions in panic symptoms. The study also documented high treatment compliance rates, positive changes in respiratory physiology, and strong evidence for safety and tolerability.
Multi-Center Trial Overview Overview A multi-center clinical trial led by David Tolin, PhD, Director of Anxiety Disorder Center, The Institute of Living and Adjunct Professor of Psychiatry at Yale University School of Medicine, was conducted at four leading non-academic anxiety treatment centers. With multiple clinical sites and treating clinicians, a larger, more diverse sample size and a broader range of co-morbid conditions, this study demonstrated that 79% of patients were panic-free and 82% had significant panic symptom reductions at 12-months. Additionally, strong adherence and safety results were replicated from an earlier study.
Highmark Health Program Overview A Quality Improvement Program conducted at Allegheny Health Network with Highmark Health provided Freespira treatment for panic, tracking clinical and health cost outcomes. 81% of subjects were panic free one year post-treatment and 94% reported significant panic symptom reductions. In addition to the clinical improvement, all-source medical spending was reduced by 50% in the year following Freespira treatment, including 53% reduction in pharmacy costs and 64% reduction in Emergency Department costs.

Freespira protocol has achieved consistent results across multiple studies

Stanford Trial*
91% Adherence
68% Panic attack free 12 months post-treatment (tx)
93% Clinically significant reduction in panic symptoms 12 months post-tx
Multi-Center Trial**
84% Adherence
71% Panic attack free immediately post-tx
79% Panic attack free 12 months post-tx
82% Clinically significant reduction in panic symptoms 12 months post-tx
88% Patient Satisfaction
Highmark Health Program†
83% Adherence
85% Panic attack free immediately post-tx
81% Panic attack free 12 months post-tx
94% Clinically significant reduction in panic symptoms 12 months post-tx
90% Patient Satisfaction
*Source: Meuret AE, Wilhelm FH & Roth WT, Feedback of End-tidal pC02 as a Therapeutic Approach for Panic Disorder, Journal of Psychiatric Research, 42:560-568, 2008.
**Source: Tolin D, McGrath P, et al, A Multisite Benchmarking Trial of Capnometry Guided Respiratory Intervention for Panic Disorder in Naturalistic Treatment Settings, Journal Applied Psychophysiology and Biofeedback, 2017, 42: 51-58.
†Source: Alicia Kaplan MD, Allegheny General Hospital, In ADAA Symposium: Abnormal Respiratory Physiology and Capnometry Guided Respiratory Intervention for Anxiety, Panic, and PTSD, 2018 Annual Conference, Anxiety and Depression Association of America

Medical Savings*

*Results specific to a large health plan Quality Improvement Program - Source: Alicia Kaplan MD, Allegheny General Hospital, In ADAA Symposium: Abnormal Respiratory Physiology and Capnometry Guided Respiratory Intervention for Anxiety, Panic, and PTSD, 2018 Annual Conference, Anxiety and Depression Association of America